Papalocal
Loading…
News
← All news
Health

FDA orders vision-loss warning added to all GLP-1 drugs, including Ozempic and Wegovy

Regulators found GLP-1 users developed a rare, potentially permanent eye condition at roughly twice the rate of comparison patients — but the absolute risk remains small and the drugs' benefits are not in question.

How does this story make you feel?

The Food and Drug Administration announced Monday that every GLP-1 drug on the U.S. market — a class of roughly a dozen injectable and pill-based medications that includes Ozempic, Wegovy, Mounjaro and Zepbound — must now carry a warning about a rare eye condition that can cause sudden, permanent vision loss.

The FDA is requiring manufacturers to add the risk to the Warnings and Precautions section of their labeling — not the more severe boxed warning — after a comprehensive review of clinical trial data, observational studies, animal data, and postmarketing reports. The condition, non-arteritic anterior ischemic optic neuropathy (NAION), has been documented in patients taking all currently marketed GLP-1 products, the agency said.

The core finding: an FDA meta-analysis of 126 randomized, controlled clinical trials involving 134,253 patients put the rate of NAION at 6.4 cases per 100,000 person-years among those taking GLP-1 drugs, versus 3.8 per 100,000 person-years for patients on a placebo or a non-GLP-1 glucose-lowering drug. Of 15 probable NAION events identified across all those trials, 10 occurred in GLP-1 users, five in placebo recipients, and none in patients on other glucose-lowering medications.

Reduced blood flow to the front of the optic nerve is what causes NAION. Its exact triggering mechanism is not fully understood, and the FDA's review of animal data found no mechanism explaining why GLP-1 drugs might increase the risk. Symptoms — which can appear upon waking — include sudden, painless vision loss in one eye, blind spots or tunnel vision, color distortion, and reduced central sharpness. The FDA is advising patients who notice any of these symptoms to contact a healthcare professional immediately.

The medicines have really been profoundly beneficial to a large number of people.— Dr. Joseph Rizzo, neuro-ophthalmologist, co-author of 2024 semaglutide-NAION study

Rizzo, whose 2024 paper in JAMA Ophthalmology first prompted the FDA's review, told CBS News he does not discourage patients from taking GLP-1 drugs. But he stressed that vision loss from NAION tends to be irreversible and can worsen even after a patient stops the medication. He also noted that the condition can affect each eye differently: mild loss in one eye does not predict what will happen to the other.

Usually when you lose vision, although there may be some mild degree of improvement, it's usually not a large degree of improvement. And unfortunately, a great frustration for so many of our patients and doctors who take care of patients with NAION is the fact that we do not really know how to mitigate the risk.— Dr. Joseph Rizzo, neuro-ophthalmologist

The evidence behind the warning is real but mixed. When the FDA conducted its own retrospective cohort study of adults with type 2 diabetes, it found no statistically significant difference in NAION risk between GLP-1 users and patients on SGLT-2 inhibitors (hazard ratio 1.19, 95% CI 0.91–1.54), though GLP-1 users did show a 43% higher risk relative to those on DPP-4 inhibitors (HR 1.43, 95% CI 1.02–2.01), according to MedPageToday. A separate Cleveland Clinic study drawing on roughly 220,000 GLP-1 users with type 2 diabetes — among them about 120,000 on semaglutide — likewise turned up no statistically significant elevation in NAION risk, according to Drug Discovery Trends.

On the other side of the ledger, two Scandinavian studies of type 2 diabetes patients on semaglutide concluded the drug was associated with increased NAION risk. A U.S. study using the TriNetX health-records network, which grouped semaglutide and tirzepatide users together, found a 76% higher NAION risk than with other diabetes drugs — recording 35 cases among 79,699 GLP-1 users versus 19 among 79,699 comparison patients over up to two years of follow-up (hazard ratio 1.76, 95% CI 1.01–3.07), according to Drug Discovery Trends. In the FDA's assessment, methodologically rigorous observational studies "consistently" showed elevated risk among patients newly starting GLP-1 drugs for type 2 diabetes when measured against those beginning DPP-4 or SGLT-2 inhibitors.

The FDA also noted that interpreting adverse event reports was difficult because NAION's known risk factors — diabetes, high blood pressure, sleep apnea, anemia, and kidney disease — are common in the same patient populations that take GLP-1 drugs.

NAION affects an estimated 2.3 to 10.2 people per 100,000 adults over age 50 per year in the general population, according to the FDA. The condition is not new to regulators: Europe's drug regulator warned about the risk 17 months before Monday's U.S. action, and a 2025 European Medicines Agency review led Novo Nordisk to list NAION as a very rare side effect in EU product leaflets, according to Drug Discovery Trends.

Novo Nordisk, maker of Ozempic and Wegovy, pushed back on the causal framing.

Continues to believe the data do not establish a cause-and-effect relationship and we remain confident in the benefit-risk profile of our GLP-1 medicines.— Novo Nordisk
Patient safety is Lilly's top priority. FDA's drug safety communication applies to all medicines with GLP-1 RA activity and does not reference any findings specific to Lilly medicines.— Eli Lilly

Eli Lilly added that it is "carefully evaluating the update and will respond to FDA promptly." According to Drug Discovery Trends, companies retain the ability to challenge the labeling language before the FDA issues a final version.

The FDA's guidance to clinicians: instruct patients to report sudden, painless vision changes immediately; refer suspected NAION cases promptly to an ophthalmologist; and consider discontinuing the GLP-1 drug if NAION develops, unless the benefits of treatment clearly outweigh the risk. Patients who have already had a NAION event should discuss with their provider whether to continue or stop the medication. Since 2025, the American Optometric Association has called for new GLP-1 users to undergo a baseline eye exam to assess optic nerve health, according to Drug Discovery Trends.

The warning lands against a backdrop of growing legal pressure: as of October 1, 247 cases were pending in federal NAION multidistrict litigation against Novo Nordisk and Eli Lilly, alleging failure to warn of the risk. According to Drug Discovery Trends, Denmark's state-and-insurer-funded patient compensation body paid out a combined 800,000 Danish kroner (about $124,000) in November 2025 to four claimants who said they had developed NAION after using Wegovy or Ozempic.

Why it matters — Tens of millions of people take GLP-1 drugs for diabetes and obesity; the new warning means patients and their doctors now need to weigh a small but real risk of irreversible vision loss — and know exactly which symptoms demand immediate medical attention.

⚠ Not yet confirmed

  • The TriNetX study found 76% higher NAION risk (HR 1.76, 95% CI 1.01–3.07) among semaglutide and tirzepatide users versus other diabetes drug users, with 35 cases in 79,699 GLP-1 users vs. 19 in 79,699 comparators over up to two years.
  • A Cleveland Clinic study of about 220,000 GLP-1 users with type 2 diabetes, including about 120,000 on semaglutide, found no statistically significant increase in NAION risk.

Sources differ on Whether GLP-1 drugs cause NAION (causal relationship): FDA says there is a 'potential increased risk' and requires a warning, but animal data found no mechanism and adverse event reports were hard to interpret due to overlapping risk factors. (fda.gov) vs Novo Nordisk 'continues to believe the data do not establish a cause-and-effect relationship.' (cbsnews.com) vs Dr. Joseph Rizzo believes the evidence shows GLP-1 usage increases the risk of developing NAION. (cbsnews.com) vs The warning is class-wide but the evidence is described as 'mixed'; one FDA cohort study found no significant risk increase vs. SGLT-2 inhibitors, while observational studies 'consistently' showed increased risk vs. DPP-4 inhibitors. (drugdiscoverytrends.com)

Reported by cbsnews.com, fda.gov, medpagetoday.com, drugdiscoverytrends.com

People in this story
  • Eli Lilly
    American pharmacist, Union Army officer, businessman, philanthropist

Community

Be the first to comment.

Share this story
Text Email